What medication changes are recommended for a 71-year-old male with early‑onset dementia, benign prostatic hyperplasia, depression, and insomnia who is taking acetaminophen (Tylenol) 650 mg twice daily, ramelteon 8 mg at bedtime, mirtazapine 15 mg at bedtime, lorazepam (Ativan) 0.5 mg twice daily plus 0.5 mg as needed twice daily, donepezil 10 mg at bedtime, and buspirone (Buspar) 7.5 mg twice daily, now exhibiting increased emotional outbursts, crying, yelling, agitation, and aggression toward staff?

Immediate Recommendation: Taper and Discontinue Lorazepam

The most critical medication change is to taper and discontinue lorazepam (Ativan), as benzodiazepines are strongly contraindicated in older adults with dementia and are likely contributing to or worsening the behavioral symptoms. The patient is receiving 1.5 mg daily (0.5 mg scheduled BID plus 0.5 mg PRN BID that he uses), which represents significant benzodiazepine exposure in a 71-year-old with dementia 1.

Why Lorazepam Must Be Stopped

The 2019 AGS Beers Criteria explicitly warns to avoid benzodiazepines in older adults due to increased risk of cognitive impairment, delirium, falls, and paradoxical agitation 1. The FDA labeling for mirtazapine specifically states to "avoid taking medicines used to treat anxiety, insomnia, and seizures, called benzodiazepines, during treatment with mirtazapine tablets" 2. This patient is on both medications concurrently, which is contraindicated.

Critical pitfall: Benzodiazepines can cause paradoxical reactions in dementia patients, manifesting as increased agitation, aggression, and emotional lability—exactly what this patient is experiencing. The lorazepam may be the primary driver of the behavioral deterioration rather than the solution.

Tapering Protocol for Lorazepam

• Reduce by 0.25 mg every 3-7 days to minimize withdrawal symptoms
• Current dose: 1.5 mg daily → 1.25 mg → 1.0 mg → 0.75 mg → 0.5 mg → 0.25 mg → discontinue
• Monitor for withdrawal symptoms: anxiety, tremor, seizures (rare at these doses but possible)
• Complete taper over 4-6 weeks

Address the Underlying Behavioral Symptoms

Step 1: Optimize Existing Medications

Increase mirtazapine from 15 mg to 30 mg at bedtime 2. The current 15 mg dose is subtherapeutic for depression. Mirtazapine at 30-45 mg has better antidepressant efficacy and may help with agitation. The FDA labeling indicates doses should be titrated to therapeutic levels 2.

Continue donepezil 10 mg - Cholinesterase inhibitors have moderate efficacy for behavioral symptoms in dementia 3.

Continue buspirone 7.5 mg BID - Buspirone has demonstrated efficacy for behavioral disturbances in dementia, with 68.6% response rate and 41.8% showing moderate to marked improvement at mean doses of 25.7 mg daily 4. Consider increasing to 10 mg BID (20 mg total daily) if symptoms persist after lorazepam taper.

Step 2: Non-Pharmacologic Interventions During Taper

The APA guidelines emphasize that nonpharmacological interventions should be reviewed prior to adding any antipsychotic medication 5. During the lorazepam taper:

• Identify and address triggers for outbursts (pain, constipation, urinary retention from BPH, environmental stressors)
• Implement structured daily routines
• Reduce environmental stimulation
• Ensure adequate pain management (current acetaminophen 650 mg BID is appropriate)

Step 3: If Symptoms Persist After Lorazepam Discontinuation

Only if behavioral symptoms remain severe, dangerous, or cause significant distress after 4-6 weeks post-lorazepam discontinuation, consider adding an antipsychotic 5. The APA guideline states antipsychotics should "only be used for the treatment of agitation or psychosis in patients with dementia when symptoms are severe, are dangerous, and/or cause significant distress to the patient" 5.

If antipsychotic becomes necessary:

• Risperidone 0.25-0.5 mg daily is conditionally recommended for aggression and psychosis 3
• Start at lowest dose, titrate slowly to minimum effective dose 5
• Reassess after 4 weeks; if no response, taper and discontinue 5
• Document informed consent discussion about mortality risk with patient's surrogate decision maker 5

Alternative Consideration: Citalopram

If depressive symptoms and agitation persist despite mirtazapine optimization, citalopram 10-20 mg daily is specifically recommended for agitation in Alzheimer's disease 3. However, this would add another medication, so optimize mirtazapine first.

Medications to Continue Unchanged

• Acetaminophen 650 mg BID: Appropriate for pain management
• Ramelteon 8 mg HS: Appropriate for insomnia in dementia, no contraindications 6
• Donepezil 10 mg HS: Continue for dementia treatment
• BPH medications: Not mentioned but should be reviewed—alpha-blockers have no significant dementia risk 7

Summary Algorithm

1. Week 0-6: Taper lorazepam by 0.25 mg every 3-7 days while increasing mirtazapine to 30 mg HS
2. Week 6-10: Observe behavioral symptoms off benzodiazepine with optimized mirtazapine
3. Week 10+: If symptoms persist, consider increasing buspirone to 10 mg BID (total 20 mg daily)
4. Only if still severe after above: Consider low-dose antipsychotic (risperidone 0.25 mg) or citalopram 10 mg with informed consent discussion

The lorazepam is almost certainly worsening this patient's behavioral symptoms and must be discontinued. The combination of benzodiazepine removal and antidepressant optimization will likely resolve the majority of behavioral issues without requiring antipsychotic medication 1, 2, 8.